in fig1 to 4 , one embodiment of a system according to the present invention is illustrated . in this embodiment , system a comprises a device 10 according to the invention , a monitor 20 for measuring a health parameter and a base station 30 for receiving the device 10 and / or monitor 20 . as depicted , the device 10 can be hand - held , portable device . the device 10 has a housing with a mouthpiece 11 . the mouthpiece 11 may be removed or replaced by a compatible mouthpiece . to this end , a connection is provided in the housing of device 10 for enabling a detachable connection with the mouthpiece 11 . alternatively , mouthpiece 11 may be an integral part of the housing of the device 10 . device 10 is also adapted to receive a cartridge or receptacle 40 holding the pharmaceutical formulation or drug . for example , the housing of device 10 can be manufactured such that cartridge 40 can simply be inserted into the top of the device as shown in fig3 . the monitor 20 can also be a hand - held , portable device as shown . monitor 20 may also have control buttons for controlling the operations of the monitor and / or a display for showing measured results and / or settings . monitor 20 can be a spirometer for measuring a lung function parameter , for example the inhalation or the exhalation capacity of the subject . the base station 30 includes cradles 32 , or the like , for holding the device 10 and monitor 20 . the base station 30 may also serve as a charger for recharging any batteries provided in device 10 and / or monitor 20 . to this end , cradles 32 may include an interface enabling an electronic connection with device 10 or monitor 20 . the interface could also enable the transfer of data between the base station 30 and the device 10 or monitor 20 . as depicted , base station 30 may also have a display 31 for displaying any desired information or data , for example the status of the base station 30 , device 10 and / or monitor 20 . base station 30 may optionally include a slot 34 for receiving a memory card , e . g . a smart card , having data with the subject &# 39 ; s aerosol parameters . in this respect , multiple users could use the base station 30 for adapting their inhalation devices 10 . base station 30 may also include an additional reader for reading a storage medium like a memory stick . although not shown , base station 30 may include communication means for enabling wired or wireless telecommunication and / or data transfer to and from a remote location . the display 31 can optionally include a timer 35 to indicate when to inhale and exhale and a communication means 36 . fig5 to 8 show an alternative embodiment of the system of the present invention . in this embodiment , system b comprises a device 100 according to the invention and a base station 300 for receiving device 100 . the device 100 and base station 300 can have the same features as device 10 and base station 30 respectively . different from device 10 , device 100 also comprises a monitor or monitoring means and can function as both inhalation device and health parameter monitor . for example , device 100 can be an integrated inhalation device and spirometer as shown in fig5 to 8 . as shown in fig7 , device 100 can also be configured to receive at least one drug cartridge 40 . in fig1 to 8 , exemplary systems are shown for respiratory disease management ( rdm ). however , modifications of the present system are possible for other types of disease management . also , variations of illustrated systems a and b are possible . for example , the base station 30 of system a may be used for receiving device 100 having an integrated spirometer and an additional monitor for measuring a health parameter such as a cardio - monitor measuring heart beat rate for example . an experiment was performed to test the effectiveness of targeting aerosolized particles to specific areas of the lungs using the methods and devices of the present invention . the experiment was made using albuterol , a drug commonly used to treat asthma as an aerosol . although commonly used in the field of asthma treatment , many patients have reported several undesirable side effects including palpitations , tremors and nervousness . it has been found in the field that the side effects of albuterol are directly related to the dose delivered and absorbed in the blood stream . fig1 illustrates a cross sectional view of a device 10 and mouthpiece 11 taken along cross section line a - a and illustrates the flow pathway 42 from the pharmaceutical formulation or drug cartridge 40 to the flow rate limiter 400 and then to the mouth piece 11 . fig1 illustrates the functional features that are included in the device 10 and which may or may not include alternative specific structural embodiments as set below . device 10 includes a flow rate limiter 400 . flow rate limiter 400 is connected to the pharmaceutical formulation or drug cartridge 40 and to the mouth piece 11 via flow pathway 42 . timer 410 controls the flow rate limiter to initiate , once a subject begins inhalation and has inhaled a first predefined time period of aerosol particle free air , a predefined volume of aerosolized particles to be introduced into the flow path , and to initiate after said predefined volume of aerosolized particles a second predefined time period of aerosol particle free air , such that the aerosolized particles are directed to bronchial and / or peripheral airways of the lungs . device 10 may also include an air control valve 420 is connected to the source of particle free air via particle free air pathway 44 . air control value 420 is typically controlled by the timer may include a piezo - controlled valve , diaphragm - activated motor , solenoid , air piston or a mechanical valve a mechanical switch . device 10 may also include a sensor 430 for detecting when a subject is inhaling through the flow path . sensor 430 is also typically , connected to the timer and may include a pressure gauge responsive to suction pressure due to the subject &# 39 ; s inhalation , a diaphragm responsive to audible intensity of the inhalation flow rate , said diaphragm preferably being a microphone , mechanical switch or a piezo membrane . as indication of the degree of bronchodilation , a spirometer was used to measure the forced expiratory volume per sec ( fev1 ) at several points in time . as an indication of the side effects of the drug , the heart rate of the subject was measured . tremor effects were measured by a finger accelerometer . for the experiment , a nebulizer was used . the nebulizer was built around a small vibrating disk that has 4 , 000 laser precision drilled holes in it . the disk was vibrated on the surface of the albuterol at more than 100 , 000 times per second . this pulled the liquid through the holes to form droplets of precise uniform size . in the experiment , data was measured for five different cases ; a , b , c , d and e , each having different aerosol parameters : in case a , a conventional device and method were used , and no targeting of the aerosolized particles was performed . a 2500 μg albuterol formulation was nebulized , which represents approximately the typical adult dose used in conventional nebulizers for achieving maximal bronchodialation . in cases b , c , d and e , the device and methods of the present invention were used . in case b , the aerosolized particles were targeted to the large airways of the lungs using a 6 - micron diameter particle size and 104 μg albuterol loaded into the device with 50 μg deposited . in case c , the aerosolized particles were targeted to the large and small airways of the lungs using a 3 . 5 - micron diameter particle size and 188 μg albuterol loaded into the device with 50 μg deposited . in case d , the aerosolized particles were targeted to the alveolar airways of the lungs using a 3 . 5 - micron diameter particle size and 98 μg albuterol loaded into the device with 50 μg deposited . in case e , the aerosolized particles were targeted to the large and small airways of the lungs using a 3 . 5 - micron diameter particle size and 282 μg albuterol loaded into the device with 75 μg deposited . referring to fig9 and 10 , the experimental results of the measured fev1 and heart rate over a period of time are depicted for cases a , b , c , d and e . although case a exhibited a maximal bronchodilation , the heart rate significantly increased thereby representing a heart attack risk for the subject . case b resulted in a notable bronchodilation , yet significantly less than the degree of bronchodilation achieved with case a . however , in contrast to case a , the heart rate remained stabile . with case c , a very good bronchodilation was achieved , which was approximately equivalent to that of case a . in contrast to case a , the heart rate remained stabile . also , a significantly lower amount of albuterol was sufficient for achieving similar degree of bronchodilation as that of case a . in case d , the same amount of albuterol was used as case c . however , the lower region ( alveolar ) of the lungs was targeted . the degree of bronchodilation was significantly lesser than that of case a . however , in contrast to case a , the heart rate remained stabile . for case e , the large and small airways were targeted as in case c . however , the deposited dose of albuterol was increased by 50 percent to 75 μg . case e resulted in very good bronchodilation with fev1 measurements being almost equivalent to those of case a . however , in contrast to case a , the heart rate remained stabile . also , as can be seen in fig9 and 10 , cases c and e had the same duration of effect as case a . cases b , c , d and e lead to less tremor effects as case a . hence , the experimental data suggest that , using significantly less than the normal dose , the present invention provides equivalent bronchodilation , equivalent duration of effect and induces less cardiac stimulation and tremor effects in particular , the experimental results show that the efficacy of a pharmaceutical formulation can be notably increased , without involving a significantly increase in dose amounts and side effects , by targeting the aerosolized formulation to certain areas of the lungs using the device of the present invention . this provides valuable advantages for the subject , especially in terms of reducing possible health risks associated with various pharmaceutical formulations . subjects would benefit by needing only a small percentage of the typical drug dose to attain the same therapeutic effects . the various embodiments and experimental results presented in the specification are used for the sake of description and clarification of the invention , and thus should not be interpreted as limiting the scope of the invention as such . moreover , the present invention is realized by the features of the claims and any obvious modifications thereof .
the present invention is directed to the administration of aerosolized particles to specific area of the lungs , and in particular to the targeted delivery of aerosolized pharmaceutical formulations to a specific area of the lungs . more specifically , the present invention relates to devices and methods for depositing aerosolized particles to a specific area of the lungs by regulating aerosolizing parameters of the device . the present invention also relates to devices , systems and methods for disease management , where the aerosolizing parameters are adjusted based on monitoring at least one health parameter .